NasdaqCM - Nasdaq Real Time Price USD

Aprea Therapeutics, Inc. (APRE)

1.8401

-0.0499

(-2.64%)

At close: June 13 at 4:00:00 PM EDT

1.8000

-0.04

(-2.18%)

After hours: June 13 at 6:59:05 PM EDT

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three patients in the 550 mg twice daily cohort in the ongoing ABOYA-119 clinical trial demonstrated tumor shrinkage of 7%, 14% and 21% ACESOT-1051, the Phase 1 trial of WEE1 inhibitor APR-1051, continues to advance, with patients now being dosed at 100 mg once daily $19.3 million in cash and cash equivalen

GlobeNewswire last month

APRE
-2.64%
Aprea doses HPV+ HNSCC subject in cohort 5 of APR-1051 trial

According to the company, the trial’s open-label data is anticipated in the latter half of this year.

Clinical Trials Arena 2 months ago

APRE
-2.64%
Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

ACESOT-1051 Trial Expanded to Include HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) Patients, Targeting Populations Most Likely to Benefit for WEEI InhibitionDOYLESTOWN, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today announced that a patient with HPV+ head an

GlobeNewswire 2 months ago

APRE
-2.64%
Aprea Therapeutics Full Year 2024 Earnings: Beats Expectations

Aprea Therapeutics ( NASDAQ:APRE ) Full Year 2024 Results Key Financial Results Net loss: US$13.0m (loss narrowed by...

Simply Wall St. 2 months ago

APRE
-2.64%
Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

ACESOT-1051 trial evaluating WEE1 kinase inhibitor APR-1051 now enrolling patients in Cohort 5; open label safety and efficacy data expected H2 2025 Twice daily (BID) dosing regimen in ongoing ABOYA-119 trial expected to maximize clinical benefit of ATR inhibitor ATRN-119; plan to complete dose escalation H2 2025 $22.8 million in cash and cash equivalents as of December 31, 2024 DOYLESTOWN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”

GlobeNewswire 2 months ago

APRE
-2.64%
Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

DOYLESTOWN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, announced today that it has entered into a Material Transfer Agreement (MTA) with MD Anderson Cancer Center. Under the agreement, Aprea will supply its proprietary WEE1 kinase inhibitor, APR-1051, to support pre

GlobeNewswire 3 months ago

APRE
-2.64%
Aprea Therapeutics provides update on existing patent portfolio

Aprea Therapeutics (APRE) provided an update on its existing patent portfolio. Aprea’s ATR inhibitor program is protected by a strong patent estate, including four granted U.S. patents, one pending U.S. application, and one pending provisional application. There are 19 granted non-U.S. patents and 16 pending non-U.S. patent applications. The granted patents will expire 2035-2037 and the pending applications, if granted, could extend exclusivity into 2044. Additional regulatory exclusivities up t

TipRanks 4 months ago

APRE
-2.64%
Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

DOYLESTOWN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company developing innovative treatments that exploit specific cancer cell vulnerabilities while minimizing damage to healthy cells, today provided an update on its existing patent portfolio. “Our strong patent portfolio reflects our commitment to innovation and leadership in the field of DNA Damage Response therapeutics,” said Oren Gilad, Ph.

GlobeNewswire 4 months ago

APRE
-2.64%
Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

Twice daily (BID) dosing regimen expected to maximize clinical benefit for patients by optimizing the activity of Aprea’s experimental drug, ATRN-119, over a 24-hour daily cycle New regimen potentially optimizes clinical outcomes and strengthens the clinical path forward ATRN-119 is the first macrocyclic ATR inhibitor to enter clinical trials DOYLESTOWN, Pa., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision oncology

GlobeNewswire 5 months ago

APRE
-2.64%
Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher

After losing some value lately, a hammer chart pattern has been formed for Aprea Therapeutics (APRE), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks 6 months ago

APRE
-2.64%
Aprea Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Aprea Therapeutics ( NASDAQ:APRE ) Third Quarter 2024 Results Key Financial Results Net loss: US$3.78m (loss widened by...

Simply Wall St. 6 months ago

APRE
-2.64%
Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates

Aprea Therapeutics (APRE) delivered earnings and revenue surprises of 14.67% and 21.11%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 7 months ago

APRE
-2.64%
Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Preliminary results from Phase 1 ACESOT-1051 trial of WEE1 inhibitor, APR-1051, demonstrate the product to be well-tolerated with no unexpected toxicities Philippe Pultar, MD engaged as senior medical advisor to support the development and advancement of APR-1051 $26.2 million in cash and cash equivalents as of September 30, 2024 with cash runway for at least twelve months DOYLESTOWN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a cl

GlobeNewswire 7 months ago

APRE
-2.64%
Pacira (PCRX) Q3 Earnings Beat Estimates

Pacira (PCRX) delivered earnings and revenue surprises of 9.72% and 0.91%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 7 months ago

APRE
-2.64%
Aprea Therapeutics presents preliminary results on APR-1051

Aprea Therapeutics (APRE) announced that preliminary safety results on its WEE1 inhibitor APR-1051 are highlighted in a poster being presented today at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place in Barcelona, Spain. Data are available on two of three patients, with a cutoff date of October 7, 2024: Preliminary results demonstrate that APR-1051 is safe and well-tolerated with no hematologic toxicity; Hemoglobin, hematocrit, and platelet counts were sta

TipRanks 7 months ago

APRE
-2.64%
Insider Spends US$132k Buying More Shares In Aprea Therapeutics

Potential Aprea Therapeutics, Inc. ( NASDAQ:APRE ) shareholders may wish to note that the Independent Director, Marc...

Simply Wall St. 7 months ago

APRE
-2.64%
Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need; active enrollment is ongoing at three sites in the U.S. Preliminary results to date demonstrate APR-1051 is safe and well-tolerated with no hematologic toxicity DOYLESTOWN, Pa., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthe

GlobeNewswire 7 months ago

APRE
-2.64%
Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

DOYLESTOWN, Pa., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that Dr. Oren Gilad, President and CEO, will participate in two presentations at the Maxim Healthcare Virtual Summit, to take place October 15 to 17, 2024. Presentation Details Session:Precision and Immune Oncology PanelDate/ time:Wednesday, October 16, 2:00 - 3

GlobeNewswire 7 months ago

APRE
-2.64%
Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

DOYLESTOWN, Pa., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that four abstracts have been accepted for poster presentation at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, to take place in Barcelona, Spain, October 23 - 25, 2024. Details on the posters are below. "We are very pleased to have

GlobeNewswire 7 months ago

APRE
-2.64%
Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

DOYLESTOWN, Pa., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today announced that it has engaged Philippe Pultar, MD as its senior medical advisor to support Aprea with developing and advancing APR-1051, Aprea’s potential best in class WEE1 inhibitor. Dr. Pultar is a seasoned pharmaceutical executive with extensive experience in oncology

GlobeNewswire 8 months ago

APRE
-2.64%

Performance Overview

Return	APRE	S&P 500 (^GSPC)
YTD	-44.07%	+1.62%
1-Year	-56.50%	+10.00%
3-Year	-88.51%	+59.40%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Aprea Therapeutics, Inc. (APRE)

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

Aprea doses HPV+ HNSCC subject in cohort 5 of APR-1051 trial

Aprea Therapeutics Announces Dosing of Patient with HPV+ Head and Neck Squamous Cell Carcinoma (HNSCC) in Ongoing ACESOT-1051 Trial

Aprea Therapeutics Full Year 2024 Earnings: Beats Expectations

Aprea Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

Aprea Therapeutics Announces Agreement with MD Anderson Cancer Center to Explore APR-1051 as a Potential Treatment for Head and Neck Squamous Cell Carcinoma (HNSCC)

Aprea Therapeutics provides update on existing patent portfolio

Aprea Therapeutics Announces Strategic IP Portfolio Evolution in DNA Damage Response (DDR) Cancer Therapeutics

Aprea Therapeutics Announces Twice Daily (BID) Dosing of Patients in ABOYA-119 Clinical Trial of ATRN-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward

Here's Why Aprea Therapeutics (APRE) Could be Great Choice for a Bottom Fisher

Aprea Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Aprea Therapeutics, Inc. (APRE) Reports Q3 Loss, Lags Revenue Estimates

Aprea Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Pacira (PCRX) Q3 Earnings Beat Estimates

Aprea Therapeutics presents preliminary results on APR-1051

Insider Spends US$132k Buying More Shares In Aprea Therapeutics

Aprea Therapeutics Presents Preliminary Findings on Oral WEE1 Inhibitor APR-1051 at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit

Aprea Therapeutics Announces Presentations at EORTC-NCI-AACR International Conference on Molecular Targets and Therapeutics

Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development

Performance Overview